Spot Vital Signs ®
and Propaq ®
LT Devices Extend Masimo SET Read-Through Motion SpO2 Monitoring Capabilities to More Patients in More Settings
Skaneateles, NY, May 16, 2007 - Welch Allyn, a
leading global manufacturer of frontline medical products and
solutions, and Masimo Corporation, the inventor of Pulse CO-Oximetry
and Read-Through Motion and Low Perfusion pulse oximetry, have
partnered to incorporate Masimo SET pulse oximetry into new versions of
the Welch Allyn Spot Vital Signs and Welch Allyn Propaq LT
devices. The two devices allow clinicians to effectively spot
check and monitor patients in multiple acuity settings within the
hospital and can be easily configured for efficient, safe and accurate
operation by caregivers with varying levels of training and
sophistication.
Masimo SET is the most accurate and reliable pulse oximetry
technology in the world, clinically proven in more than 100 independent
and objective studies to provide the most trustworthy arterial blood
oxygen saturation and pulse rate measurements even under the most
difficult clinical conditions, including patient motion and low
peripheral perfusion. These studies prove Masimo SET delivers
improvements in outcomes, safety and efficiency while decreasing costs.
"We are very pleased to extend our current business relationship
with Masimo as we strive to offer our customers the safest and most
accurate monitoring technologies available," said Doug Linquest,
executive vice president, Monitoring and Defibrillation at Welch
Allyn. "By continuing to integrate Masimo SET pulse
oximetry technology into our extensive line of spot-check and
monitoring systems, we are able to give caregivers the capability to
monitor SpO2 in more patients in places they never thought possible."
Spot Vital Signs is a fully automated, multiparameter spot-check
device that captures non-invasive blood pressure measurements using the
oscillometric method. In addition to a pulse oximetry option, it
also offers Welch Allyn's SureTemp® fast predictive thermometry which
gives providers the option of performing oral, axillary or rectal
temperature readings. Spot Vital Signs can also transfer data
from the device into patients' medical records via an infrared
connection designed to interface with the Welch Allyn Connex™ Data
Management System.
The Propaq LT patient monitor can be used in a number of bedside,
transport and ambulatory applications. It is deployable in areas
in and outside the hospital, and comes equipped to monitor heart rate,
3- or 5-lead ECG, non-invasive blood pressure, SpO2,
and respiration with an easy-to-use interface. It features a
full-color LCD screen and can be configured for use on neonatal,
pediatric and adult patients. The Propaq LT can be operated in
standalone mode or wirelessly networked to Welch Allyn's Acuity Central
Monitoring Station, and it can easily download data to a PC and
customer Electronic Medical Records (EMR.)
"One of Welch Allyn's top priorities is to bring patient monitoring
to the presently unmonitored bed, which makes up over eighty percent of
today's hospital beds," added Linquest. "These beds are typically
general care or medical-surgical beds and require advanced and
connected spot-check vital signs devices. The new Propaq LT monitor
effectively bridges the gap (cost, size and complexity) between today's
continuous patient monitors and spot-check devices like Spot Vital
Signs that offer even more comprehensive clinical benefits to the
unmonitored bed."
"This partnership confirms the strength of our business relationship
with Welch Allyn and the commitment of both companies to bring best in
class patient monitoring technology to new clinical sites," said Joe E.
Kiani, Chairman and CEO of Masimo Corporation. "We are happy that by
partnering with Welch Allyn, we can offer the proven benefits of Masimo
SET pulse oximetry to more clinicians and patients in more diverse
clinical settings."
For more information about Welch Allyn vital signs capture and monitoring devices, please call 800.535.6663 or visit www.welchallyn.com.
About Welch Allyn
Welch Allyn, Inc. was founded
in 1915 and is today a leading manufacturer of innovative medical
diagnostic and therapeutic devices, cardiac defibrillators, patient
monitoring systems, and miniature precision lamps. Headquartered in
Skaneateles Falls, New York, USA, Welch Allyn employs more than 2,300
people and has numerous manufacturing, sales, and distribution
facilities located throughout the world. Additional information on
Welch Allyn and its products may be found at www.welchallyn.com.
About Masimo
Masimo develops innovative
monitoring technologies that significantly improve patient care-helping
solve "unsolvable" problems. In 1995, the company debuted Read-Through
Motion and Low Perfusion pulse oximetry, known as SET and with it
virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent
clinical studies have confirmed that Masimo SET technology allows
clinicians to accurately monitor blood oxygen saturation in critical
care situations-establishing the technology as the "gold standard"
pulse oximetry and substantially contributing to improved patient
outcomes. In 2005 Masimo introduced Masimo Rainbow SET Pulse
CO-Oximetry, which, for the first time, noninvasively monitors the
level of carbon monoxide and methemoglobin in the blood, allowing early
detection and treatment of potentially life-threatening conditions.
Masimo, founded in 1989, has the mission of "Improving Patient Outcomes
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications." Additional information about Masimo and its products
may be found at www.masimo.com.
Contact Welch Allyn:
Jamie Arnold
Public Relations Manager
315.685.4599
arnoldj@welchallyn.com
Contact Masimo:
Tom McCall
Masimo Corporation
949-297-7075
tmccall@masimo.com